** Shares of Neurotech International NTI.AX rise as much as 10.6% to A$0.073, posting their biggest intraday percentage gain since Aug. 14
** Stock hits its highest level since Sept. 9
** Biopharmaceutical co says the U.S. Food and Drug Administration granted the orphan drug status to its NTI164 drug, aimed at treating Rett Syndrome
** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.
** About 1.6 mln shares change hands, compared with the 30-day average volume of around 601,000
** Stock up 1.5% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。